Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 5OTHER 4NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Has results × Megestrol Acetate × Clear all
NCT00729586 2019-07-23

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡